Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (August 2021)
28 slides from Clearpoint Neuro's investor presentation, Aug 10, 2021
Slide 1: ClearPoint Neuro
CLEARPOINT NEURO WHEN YOUR PATE WE POINT THE WAY. Nasdaq: CLPT August 2021
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's
Slide 3: Our Company: Two Opportunities, One Platform
Our Company ClearPoint Neuro: Two Opportunities, One Platform CLEARPOINT Leveraging a Common Navigation Engine, Installed Base and Clinical Support Channel A Biologics & Drug Delivery Company with a Broad Portfolio A Medical Device Company with an Innovative of Pharma Partners and Indications with P
Slide 4: Our Company: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Products: FDA C€ Marked Platforms HEADQUARTERS MANUFACTURING EUROPEAN HEADQUARTERS Solana Beach, CA _ Irvine, CA Manchester, UK 2020 REVENUE CASH A) $12.8m 361.5m “Tl U.S. PATENTS ISSUED GROSS MARGIN Razor / Razorblade 0 65 67%” model with 85+ % of
Slide 5: Limitations of Traditional Stereotactic Neurosurgery
Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible etee CLE
Slide 6: Our Platform — Procedure Overview
Our Platform — Procedure Overview The ClearPoint® Neuro Navigation System esse CLEARPOINT © 2021 CLEARPOINT NEURO 6 33° NEURO
Slide 7: SmartFrame XG / SmartFrame Array
SmartFrame® XG SmartFrame Array™ SmartFrame Array Tower* with “virtual array” Software and next generation robotic system with increased automation and enabling software SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software ¢; CLEARPOINT © 2021 CLEARPOINT NEURO 7 *The SmartFrame Array Tower, S
Slide 8: Our Platform: The ClearPoint Maestro Brain Model
Our Platform The ClearPoint ‘Maestro’ Brain Model” Licensed and Jointly Developed with Philips 1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects 2. Fast and capable of peri-procedural imaging without CPU acceleration 3. This model is the basis fo
Slide 9: Our MRI-guided therapy platform is currently being used to...
Our MRI-guided therapy platform is currently being used to... SIEMENS PTC) Medtronic Medtronic SID —) Abbott MONTERIS’ ey) BlueRock Therapeutics Boston = Scientific %5ENE a uniQure © IMRIS YJ — NEUROPACE charles river ..with ~35 commercial and academic partners *- CLEARPOINT © 2021 CLEARPOINT NEURO
Slide 10: ...and Growing Globally
U... and'Growing Globall -UC San Feanciscol University of Wiscons x: ‘Labs (Laval, Canada) Rigshospitalet (Copent : Stanford University University of Michigan - » 9 © . | Children’s Mercy Hospital - . . » Mazowiecki Szpital Brodnowski Hit y of CHOA Scottish Rite ‘ 4 “UCSF Benioff Children’s . le Bon
Slide 11: Biologics & Drug Delivery
Biologics & Drug Delivery © 2021 CLEARPOINT NEURO
Slide 12: Why ClearPoint?
Why ClearPoint? Benefits of ClearPoint 1. Select and confirm the most accurate trajectory before insertion using live MRI Guidance 2. Identify peri-procedural safety issues live instead of after the patient is closed (i.e., hemorrhage) 3. Confirm proper target coverage with drug before closing the p
Slide 13: Biologics & Drug Delivery Patient Treatment Opportunity per Year
PATIENT TREATMENT OPPORTUNITY/YEAR 1. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for G 200,000 Parkinson’s Disease** 100,000 ~$1.2B3 10,000 Huntington ALS Disease** ~$120M* ~$120M? 3 Angelman 5,000 Syndrome 4 Friedreich’s ¥ ~$72M! Multiple System Ataxia** Atrophy ~$60M
Slide 14: Specialized Consultation for Pharmaceutical Customers
1. Biologics & Drug Delivery Specialized Consultation for Pharmaceutical Customers Custom Protocol Solutions for Cannula Builds Consultation Pre-Clinical Programs 2) O00 - Ch Network of On-Site Data Neurosurgeons Clinical Support Management eit; CLEARPOINT © 2021 CLEARPOINT NEURO
Slide 15: Navigation Device & Therapy
Navigation Device & Therapy © 2021 CLEARPOINT NEURO
Slide 16: The ClearPoint Neuro Navigation Platform for DBS
The ClearPoint® Neuro Navigation Platform is used to accurately place leads in the appropriate targeted structure. The leads are connected in a separate procedure to a neurostimulator implanted near the collarbone. Deep brain stimulation (DBS) uses a surgically implanted medical device, similar to a
Slide 17: Deep Brain Stimulation: Gaining Share in a Growing Market
tion (DBS) Deep Brain Stimulation Gaining Share in a Growing Market Seieitific Medtronic a ater Parkinson’s Patient Population (US) 1.2M Patients with Parkinson’s disease 1M Patients diagnosed and treated (+60K newly diagnosed/year) 240K ~24% eligible for DBS 5% actual implants/year NELROPACE 2019 4
Slide 18: Neuro Navigation (DBS)
2. Neuro Navigation (DBS) Improved Navigation & Technology, New Indications Drive DBS Market Growth of 10%+ CAGR 2020-2025 New Indicati in Trials P Neurosurgical Targets Pilot Phase I/II Phase Ill © Commercial Epilepsy 2 million+ Multiple Obsessive Compulsive 10 million+ Ventral internal capsule/ Di
Slide 19: New Therapy Devices: ClearPoint Neuro Laser Therapy
3. New Therapy Devices ClearPoint Neuro Laser Therapy — Capturing the Entire Procedure LITT uses laser energy to destroy unwanted cells * Today MRI is required during LITT procedures to precisely monitor and control the temperature and thermal dose from that laser. * ClearPoint is chosen by Neurosur
Slide 20: New Therapy Devices: Addressable Neuro Market in Epilepsy and Tumor
3. New Therapy Devices ClearPoint Neuro Laser Therapy” — Capturing the Entire Procedure Significant Addressable Neuro Market in Epilepsy and Tumor *, MONTERIS’ Medtronic = -*.°:. MONTE! LiTT for Epil - Total Addi ble Patient Population (US) 150K Patients with Epilepsy 50K Epileptic Patients Resistan
Slide 21: New Global Showcase Site
New Global Showcase Site ClearPoint Cove Training and Innovation Center - Solana Beach, CA ¢ Intimate training experience for surgeons and staff to perform mock procedures and provide pipeline feedback ¢ Showcase new technology for Pharmaceutical Drug Delivery partners ¢ Home for remote support spec
Slide 22: Innovation: Accelerated Product Pipeline
Innovation Accelerated Product Pipeline and Target First Clinical Use 2020-21 Navigation & Robotics * A 2022 2023 ve a e¢ ® (CRN) Inflexion™ Head SmartFrame ClearPoint Neuro Navigation ClearPoint Maestro™ ClearPoint Maestro™ ClearPoint Revolution” Fixation Frame Array™! Software v. 2.1? Brain Model?
Slide 23: Global Scale: 4 Pillar Growth Strategy by 2025
GLOBAL SCALE Expand Footprint OUS Open WW Training / Remote Support Facility 4 Pillar Growth Strategy by 2025 Launch Robotic Platform Target Indications of > 150,000 procedures per year represents Potential Addressable Market for CLPT of $1B+ NEW THERAPY DEVICES Launch Maestro Brain Model and Apps E
Slide 24: Financials
Financials
Slide 25: Growth in Case Volume and Revenue
2013 - 2021 Growth in Case Volume and Revenue impact on Elective -edures 670 - 629 503 380 267 ; | 2013-2014 «2015 = _2016 «= 2017. «Ss 2018 += 2019 -»S 2020S 2021 see CLEARPOINT
Slide 26: CLPT Capabilities: Executive Summary
CLPT CAPABILITIES Executive Summary : ww — Unique Platform technology Total potential addressable market [sx] enabling Precision MRI-Guided Therapies () > $1B for our products and pipeline to restore quality of life for some of the most debilitating disorders Pipeline of new revenue streams Lange, G
Slide 27: sda
sda poss Pomposite ome * O:F are ~ 18% 3,900.02 9 COMP * 0.20% 19.29% du v 0.0972 : 19.21 9,731.18 te ill +2788 9,623.58 - “comtast amazon” BP on 0.04% hah, 4 cisco. COMCAST pepsico matchgroup @ 2. GMcsA soe, ment eucsa “0.04% PEP * 0.36% “1.72% SBUX ve fae em SE_PEN Nasda DOWIONES— Composite Nasdaq
Slide 28: Oo a &
= a Oo 5 a & eoee ry |, {Zz Lu — O
ClearPoint Neuro — Investor Presentation (August 2021) on 6ix